aTyr Pharma Stock Takes a Hit After Phase 3 Trial Miss
aTyr Pharma stock falls over 80% following disappointing Phase 3 trial results for efzofitimod, its drug for pulmonary sarcoidosis.
Phase 3 trial
aTyr Pharma stock falls over 80% following disappointing Phase 3 trial results for efzofitimod, its drug for pulmonary sarcoidosis.
